ImmunoPrecise Antibodies Ltd (IPA) NPV

Sell:$0.39Buy:$0.41$0.01 (1.52%)

Prices delayed by at least 15 minutes
Sell:$0.39
Buy:$0.41
Change:$0.01 (1.52%)
Prices delayed by at least 15 minutes
Sell:$0.39
Buy:$0.41
Change:$0.01 (1.52%)
Prices delayed by at least 15 minutes

Company Information

About this company

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.

Key people

Mitch Levine
Chairman of the Board
Jennifer Lynne Bath
President, Chief Executive Officer, Director
Joseph Scheffler
Interim Chief Financial Officer
Ilse Roodink
Chief Scientific Officer
Kari Graber
Vice President - Commercial Services
Lisa Helbling
Director
Kamil Isaev
Director
Robert D. Burke
Independent Director
Barry A. Springer
Independent Director
Dirk Witters
Independent Director
Click to see more

Key facts

  • EPIC
    IPA
  • Location
    Canada
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    CA45257F2008
  • Market cap
    $16.14m
  • Employees
    102
  • Shares in issue
    45.77m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.